-
'1 Report Prologue
-
Executive Summary
-
Market Introduction
-
Definition 26
-
Scope Of Study
-
List Of Assumptions 26
-
Market Structure 27
-
Research Methodology
-
Research Process 29
-
Primary
-
Research 30
-
Secondary Research 31
-
Market Size Estimation
-
Forecast Model 32
-
Market Dynamics
-
Introduction 34
-
Drivers 35
- Increasing Preference
-
For Minimally Invasive Procedures 35
-
Rising Prevalence Of Chronic
-
Disorders 36
-
Improvement In Reimbursement Scenario 37
- Rising Geriatric Population 38
-
Restraints 39
-
Rising Treatment Cost And Hospital Stay 39
-
Lack Of Skilled Physicians
-
Opportunities 41
- New Advancements In Catheterization
-
Devices 41
-
Guide Wire Assisted Surgery In Elderly Population 41
-
Mega Trends 41
- Telemedicine 41
-
Macroeconomic
-
Indicators 41
-
Technology Trends & Assessment 42
-
Market Factor Analysis
-
Porter’s Five Forces Model 44
- Threat Of New Entrants 44
- Bargaining Power Of Suppliers
- Threat Of Substitutes 45
- Bargaining Power Of
-
Buyers 45
-
Intensity Of Rivalry 45
-
Supply Chain Analysis
- Research &Development 46
- Manufacturing
- Distribution 46
- Marketing & Sales 47
- Post-Sales Monitoring 47
-
Demand & Supply: Gap Analysis
-
Pricing Analysis 47
-
Investment Feasibility Analysis
-
Global Transient Ischemic Attack Market, By Diagnosis
-
Introduction 49
-
Imaging Techniques 49
- Computed Tomography
-
(CT) Scan 51
-
Carotid Duplex Scanning 51
- Magnetic
-
Resonance Imaging 52
-
Echocardiography 52
-
Global Transient
-
Ischemic Attack Market, By Treatment
-
Introduction 54
-
Surgery 54
-
Drugs 54
- Surgery 55
-
Drugs 56
-
Antithrombotic Agents 56
- Antiplatelets
-
Heparins 57
-
ENOXAPARIN 58
- DALTEPARIN 58
-
Alteplase 59
-
Antihypertensive Agents 59
-
Prazosin 60
-
Moxonidine 60
-
Global Transient Ischemic
-
Attack Market, By Age Groups
-
Introduction 62
-
Years 62
-
19–40 Years (Millennial) 62
-
Years 62
-
60+ Years 63
- 0-18 Years 64
-
40 Years 65
-
41-60 Years 65
- 60+ Years 65
-
Global Transient Ischemic Attack Market, By End-User
-
Introduction 67
-
Hospitals & Clinics 67
-
Diagnostic
-
Centers 67
-
Research Laboratories 68
- Hospitals
- Diagnostic Centers 70
- Research Laboratories
-
Global Transient Ischemic Attack Market, By Region
-
Introduction 72
-
Americas 73
- North America 78
- South America
-
Europe 94
- Western Europe
-
U.K. 111
-
Italy 115
- Spain 119
-
Rest Of Western Europe 123
-
Eastern Europe 127
-
Asia Pacific 131
-
Asia Pacific 132
- Japan 136
- China 140
- India 144
- Australia
- Republic Of Korea 152
- Rest Of Asia Pacific
-
The Middle East & Africa 160
- Middle East
-
And Africa 161
-
United Arab Emirates 164
- Saudi
-
Arabia 168
-
Rest Of Middle East & Africa 172
-
Competitive Landscape
-
Company Market Share Analysis 177
- Introduction 177
-
Company Share Analysis 178
-
Recent Developments, 2013–2018 179
-
Company Profiles
-
Koninklijke Philips N.V. 184
- Company Overview 184
- Financial Overview 184
- Products Offering 185
- Key Developments 185
- SWOT Analysis 185
-
Key Strategy 186
-
Stryker Corporation 187
- Company
-
Overview 187
-
Financial Overview 187
- Products
-
Offering 188
-
Key Developments 188
- SWOT Analysis
- Key Strategy 189
-
Johnson & Johnson Services
-
Inc. 190
-
Company Overview 190
- Financial Overview
- Products Offering 191
- Key Developments 191
- SWOT Analysis 192
- Key Strategy 192
-
Boston Scientific Corporation 193
-
Company Overview 193
- Financial Overview 193
- Products Offering 194
- Key Developments 195
- SWOT Analysis 195
-
Key Strategy 195
-
Sanofi 196
- Company Overview 196
- Financial Overview 196
- Products Offering 197
- Key Developments 197
- SWOT Analysis 197
- Key Strategy 197
-
Bayer AG 198
- Company
-
Overview 198
-
Financial Overview 198
- Products
-
Offering 199
-
Key Developments 199
- SWOT Analysis
- Key Strategy 199
-
Pfizer Inc. 200
- Company Overview 200
- Financial Overview 200
- Products Offering 201
- Key Developments 201
-
SWOT Analysis 201
-
Key Strategy 201
-
Siemens AG
- Company Overview 202
- Financial Overview
- Products Offering 203
- Key Developments 203
- SWOT Analysis 203
- Key Strategy 203
-
F. Hoffmann-La Roche AG 204
-
Company Overview 204
-
Financial Overview 204
-
Products Offering 205
-
Key Developments 205
-
SWOT Analysis 205
- Key Strategy
-
GE Healthcare 206
- Company Overview 206
- Financial Overview 206
- Products Offering 207
- Key Developments 207
- SWOT Analysis 207
- Key Strategy 207
-
Penumbra, Inc. 208
-
Company Overview 208
-
Financial Overview 208
-
Products Offering 209
-
Key Developments 209
-
SWOT Analysis 209
-
Key Strategy 210
-
Medtronic
-
PLC 211
-
Company Overview 211
- Financial Overview
- Products Offering 212
- Key Developments
- SWOT Analysis 212
- Key Strategy 213
-
Abbott Laboratories 214
- Company Overview 214
- Financial Overview 214
- Products Offering 215
- Key Developments 215
- SWOT Analysis 216
- Key Strategy 216
-
Merck & Co., Inc. 217
-
Company Overview 217
-
Financial Overview 217
-
Products Offering 218
-
Key Developments 218
-
SWOT Analysis 218
-
Key Strategy 218
-
Boehringer
-
Ingelheim GmbH 219
-
Company Overview 219
- Financial
-
Overview 219
-
Products Offering 220
- Key Developments
- SWOT Analysis 220
- Key Strategy 220
-
Conclusion
-
Key Findings 222
- CEO’s
-
Viewpoint 222
-
Unmet Needs 222
- Key Companies
-
To Watch 222
-
Prediction 222
-
Appendix
-
Discussion Blue Print 224
-
References 225
-
List Of Tables
-
ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027
-
(USD MILLION) 50
-
IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,
-
(USD MILLION) 51
-
IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,
-
–2027 (USD
-
MILLION) 51
-
TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,
-
–2027 (USD MILLION)
-
BY ECHOCARDIOGRAPHY,
-
–2027 (USD MILLION) 52
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION)
-
SURGERY, 2020–2027 (USD MILLION) 55
-
ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56
-
–2027 (USD MILLION) 56
-
MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
–2027 (USD
-
MILLION) 56
-
BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57
-
ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION)
-
AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57
-
TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD
-
MILLION) 58
-
BY DALTEPARIN, 2020–2027 (USD MILLION) 58
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
(USD MILLION) 58
-
FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027
-
(USD MILLION) 59
-
DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,
-
–2027 (USD MILLION) 60
-
ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,
-
(USD MILLION) 60
-
AGE GROUPS, 2020–2027 (USD MILLION) 63
-
ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION)
-
40 YEARS, 2020–2027 (USD MILLION) 65
-
ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION)
-
+ YEARS, 2020–2027 (USD MILLION) 65
-
ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027
-
(USD MILLION) 69
-
DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70
-
GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION,
-
–2027 (USD MILLION) 70
-
MARKET, BY REGION, 2020–2027 (USD MILLION) 72
-
TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73
-
(USD MILLION) 74
-
DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74
-
AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD
-
MILLION) 74
-
BY DRUGS, 2020–2027 (USD MILLION) 75
-
ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD
-
MILLION) 75
-
AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION) 75
-
AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
-
–2027 (USD MILLION) 76
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
(USD MILLION) 76
-
DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76
-
AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
-
MILLION) 77
-
–2027 (USD MILLION) 77
-
ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
-
AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
-
BY IMAGING TECHNIQUE,
-
–2027 (USD MILLION) 79
-
NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027
-
(USD MILLION) 79
-
FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79
-
AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
-
–2027 (USD MILLION) 80
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
(USD MILLION) 80
-
FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
-
–2027 (USD MILLION)
-
AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 81
-
NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
-
AGENTS,
-
–2027 (USD MILLION) 81
-
TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
-
(USD MILLION) 82
-
–2027 (USD MILLION) 82
-
MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82
-
(USD MILLION) 83
-
BY DRUGS, 2020–2027 (USD MILLION) 83
-
ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
-
AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION) 84
-
U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
-
–2027 (USD MILLION) 84
-
MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD
-
MILLION) 84
-
BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85
-
U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
-
(USD MILLION) 85
-
DIAGNOSIS, 2020–2027 (USD MILLION) 86
-
ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
-
MILLION) 86
-
–2027 (USD MILLION) 86
-
MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87
-
CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
-
–2027 (USD MILLION) 87
-
MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
–2027 (USD
-
MILLION) 87
-
AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88
-
TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 88
-
ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
-
(USD MILLION) 89
-
END-USER, 2020–2027 (USD MILLION) 89
-
ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
-
TECHNIQUE,
-
–2027 (USD MILLION) 90
-
AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
-
BY DRUGS, 2020–2027 (USD MILLION) 91
-
ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
-
(USD MILLION) 91
-
FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION)
-
AGENTS, BY HEPARINS,
-
–2027 (USD MILLION) 92
-
SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY
-
FIBRINOLYTICS,
-
–2027 (USD MILLION) 92
-
AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
-
–2027 (USD MILLION) 92
-
ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93
-
(USD MILLION) 93
-
COUNTRY, 2020–2027 (USD MILLION) 94
-
ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027
-
(USD MILLION) 95
-
TREATMENT,, 2020–2027 (USD MILLION) 95
-
ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96
-
AGENTS, 2020–2027 (USD MILLION) 96
-
ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
(USD MILLION) 96
-
ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 97
-
ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
-
(USD MILLION) 98
-
END-USER, 2020–2027 (USD MILLION) 98
-
ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99
-
TECHNIQUE,
-
–2027 (USD MILLION) 99
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
-
BY DRUGS, 2020–2027 (USD MILLION) 100
-
TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
-
(USD MILLION) 100
-
MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
–2027 (USD
-
MILLION) 100
-
FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
-
–2027 (USD MILLION)
-
AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 101
-
AGENTS,
-
–2027 (USD MILLION) 101
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
-
–2027 (USD MILLION) 102
-
ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103
-
GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
-
–2027 (USD MILLION) 103
-
ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103
-
GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
-
(USD MILLION) 104
-
FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104
-
BY ANTIPLATELETS,
-
–2027 (USD MILLION) 104
-
GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
-
–2027 (USD MILLION) 105
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
(USD MILLION) 105
-
FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105
-
(USD MILLION) 106
-
BY END-USER, 2020–2027 (USD MILLION) 106
-
ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
-
–2027 (USD MILLION) 107
-
ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107
-
FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
-
(USD MILLION) 108
-
DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108
-
FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION) 108
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD
-
MILLION) 109
-
AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 109
-
AGENTS, 2020–2027 (USD MILLION) 109
-
ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110
-
(USD MILLION) 110
-
DIAGNOSIS, 2020–2027 (USD MILLION) 111
-
ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
-
MILLION) 111
-
–2027 (USD MILLION) 111
-
MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112
-
U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027
-
(USD MILLION) 112
-
ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112
-
–2027 (USD MILLION) 113
-
MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION)
-
AGENTS, 2020–2027 (USD MILLION) 113
-
ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114
-
U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION)
-
(USD MILLION) 115
-
DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115
-
ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
-
DRUGS, 2020–2027 (USD MILLION) 116
-
ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
-
AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION) 116
-
HEPARINS, 2020–2027 (USD MILLION) 117
-
ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
(USD MILLION) 117
-
DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117
-
ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
-
(USD MILLION) 118
-
DIAGNOSIS, 2020–2027 (USD MILLION) 119
-
ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
-
MILLION) 119
-
–2027 (USD MILLION) 119
-
ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120
-
AGENTS, 2020–2027 (USD MILLION) 120
-
ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
-
(USD MILLION) 120
-
ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121
-
SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 121
-
ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
-
(USD MILLION) 122
-
END-USER, 2020–2027 (USD MILLION) 122
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
-
FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
-
–2027 (USD MILLION) 123
-
–2027 (USD MILLION) 123
-
ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124
-
BY ANTITHROMBOTIC AGENTS,
-
–2027 (USD MILLION) 124
-
AGENTS, BY ANTIPLATELETS,
-
–2027 (USD MILLION) 124
-
AGENTS, BY HEPARINS,
-
–2027 (USD MILLION) 125
-
REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS,
-
BY FIBRINOLYTICS,
-
–2027 (USD MILLION) 125
-
REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
-
AGENTS,
-
–2027 (USD MILLION) 125
-
WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
-
MILLION) 126
-
MARKET, BY END-USER, 2020–2027 (USD MILLION) 126
-
EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
-
BY IMAGING TECHNIQUE,
-
–2027 (USD MILLION) 127
-
EASTERN EUROPE TRANSIENT ISCHE'